FibroBiologics
NASDAQ: FBLGHouston, US · Founded 2021 · Delaware corporation
FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.
BiotechHealthtechLongevity
Founders & leadership
PO
Pete O'HeeronChairman, Founder and Chief Executive Officer
JD
Jason D. DavisChief Financial Officer
SC
Stacy CoenDirector
ML
Matthew LinkDirector
RH
Robert HoffmanDirector
VN
Victoria NiklasDirector
RC
Richard C. CilentoDirector
Reported raises · per SEC filings
Form D private placements▶$3MraisedJun 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJun 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
- Robert HoffmanDirector
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Victoria NiklasDirector
- Matthew LinkDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $315K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.7MraisedDec 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert HoffmanDirector
- Matthew LinkDirector
- Stacy CoenDirector
- Jason D. DavisExecutive Officer
- Pete O'HeeronExecutive Officer, Director
- Richard C. CilentoDirector
- Victoria NiklasDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Sales commissions
- $329.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$4MraisedDec 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedDec 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Stacy CoenDirector
- Victoria NiklasDirector
- Matthew LinkDirector
- Robert HoffmanDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedDec 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stacy CoenDirector
- Matthew LinkDirector
- Robert HoffmanDirector
- Victoria NiklasDirector
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Sales commissions
- $292.2K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $252K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.